# A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

> **NCT06415669** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 30 (estimated)

## Conditions studied

- Gastric/Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Paclitaxel for injection (albumin-bound)
- **DRUG:** Adebrelimab
- **DRUG:** Apatinib mesylate

## Key facts

- **NCT ID:** NCT06415669
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-19
- **Primary completion:** 2026-05-19
- **Final completion:** 2027-05-19
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06415669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06415669, "A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06415669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*